Multiparametric Imaging in Multiple Myeloma



Status:Active, not recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:40 - 75
Updated:9/20/2018
Start Date:July 2016
End Date:June 2021

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography
imaging with intravenously injected C11 Methionine to detect viable lesions.


Inclusion Criteria:

- Diagnosis of Multiple Myeloma with symptomatic bone or soft tissue disease

- Eastern Cooperative Oncology Group status 0 to 2

- Life expectance >= 12 weeks

- Ability to understand and willingness to sign informed consent

- Tissue sampling with genotype data planned within 3 months of C11 positron emission
tomography (PET) imaging

Exclusion Criteria:

- Pregnant or breast feeding

- Claustrophobic reactions and unable to lie still on a bed inside the PET scanner for
60 minutes

- Research related radiation exposure exceeding 50 millisieverts
We found this trial at
1
site
Massachusetts General Hospital
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Phone: 617-726-2000
?
mi
from
Boston, MA
Click here to add this to my saved trials